- $76.07bn
- $92.72bn
- £31.38bn
- 78
- 65
- 86
- 90
Annual balance sheet for GSK, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6,370 | 4,335 | 7,877 | 4,992 | 3,714 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7,264 | 8,031 | 7,115 | 7,403 | 6,935 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20,247 | 18,674 | 20,769 | 18,644 | 16,997 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11,006 | 10,672 | 9,620 | 9,957 | 10,073 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 80,431 | 79,103 | 60,146 | 59,005 | 59,463 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22,148 | 23,670 | 22,810 | 21,068 | 21,697 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 65,844 | 64,048 | 49,548 | 45,658 | 45,792 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 14,587 | 15,055 | 10,598 | 13,347 | 13,671 |
Total Liabilities & Shareholders' Equity | 80,431 | 79,103 | 60,146 | 59,005 | 59,463 |
Total Common Shares Outstanding |